|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KLK13 |
Gene summary for KLK13 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KLK13 | Gene ID | 26085 |
| Gene name | kallikrein related peptidase 13 | |
| Gene Alias | KLK-L4 | |
| Cytomap | 19q13.41 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | Q5BQ99 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26085 | KLK13 | LZE24T | Human | Esophagus | ESCC | 4.29e-20 | 1.09e+00 | 0.0596 |
| 26085 | KLK13 | P8T-E | Human | Esophagus | ESCC | 4.23e-41 | 1.27e+00 | 0.0889 |
| 26085 | KLK13 | P27T-E | Human | Esophagus | ESCC | 8.12e-10 | 4.10e-01 | 0.1055 |
| 26085 | KLK13 | P28T-E | Human | Esophagus | ESCC | 9.03e-15 | 3.61e-01 | 0.1149 |
| 26085 | KLK13 | P47T-E | Human | Esophagus | ESCC | 2.20e-03 | 2.03e-01 | 0.1067 |
| 26085 | KLK13 | P61T-E | Human | Esophagus | ESCC | 2.07e-02 | 2.74e-01 | 0.099 |
| 26085 | KLK13 | P74T-E | Human | Esophagus | ESCC | 8.62e-36 | 2.01e+00 | 0.1479 |
| 26085 | KLK13 | P127T-E | Human | Esophagus | ESCC | 6.53e-14 | 7.64e-01 | 0.0826 |
| 26085 | KLK13 | P128T-E | Human | Esophagus | ESCC | 1.29e-23 | 1.02e+00 | 0.1241 |
| 26085 | KLK13 | C21 | Human | Oral cavity | OSCC | 1.81e-15 | 7.57e-01 | 0.2678 |
| 26085 | KLK13 | C08 | Human | Oral cavity | OSCC | 3.27e-02 | 1.43e-01 | 0.1919 |
| 26085 | KLK13 | LP15 | Human | Oral cavity | LP | 6.56e-03 | 1.84e+00 | 0.2174 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KLK13 | SNV | Missense_Mutation | novel | c.304N>A | p.Glu102Lys | p.E102K | Q9UKR3 | protein_coding | tolerated(0.61) | benign(0.012) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KLK13 | SNV | Missense_Mutation | c.173N>A | p.Arg58Gln | p.R58Q | Q9UKR3 | protein_coding | tolerated(0.17) | benign(0.014) | TCGA-D8-A1X8-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adrimicin+cyclophosphamide | SD | |
| KLK13 | SNV | Missense_Mutation | c.559N>A | p.Glu187Lys | p.E187K | Q9UKR3 | protein_coding | tolerated(0.56) | benign(0.165) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| KLK13 | SNV | Missense_Mutation | novel | c.541N>G | p.Ile181Val | p.I181V | Q9UKR3 | protein_coding | tolerated(0.28) | benign(0.048) | TCGA-S3-AA17-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
| KLK13 | SNV | Missense_Mutation | c.547C>T | p.Leu183Phe | p.L183F | Q9UKR3 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| KLK13 | SNV | Missense_Mutation | rs747541094 | c.568C>T | p.Arg190Cys | p.R190C | Q9UKR3 | protein_coding | deleterious(0.01) | possibly_damaging(0.901) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| KLK13 | SNV | Missense_Mutation | c.482N>A | p.Gly161Asp | p.G161D | Q9UKR3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| KLK13 | SNV | Missense_Mutation | rs142773664 | c.569G>A | p.Arg190His | p.R190H | Q9UKR3 | protein_coding | tolerated(0.28) | benign(0.014) | TCGA-D5-5538-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | calcium | PD |
| KLK13 | SNV | Missense_Mutation | rs200725984 | c.172C>T | p.Arg58Trp | p.R58W | Q9UKR3 | protein_coding | deleterious(0) | possibly_damaging(0.894) | TCGA-F4-6854-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KLK13 | SNV | Missense_Mutation | c.365A>G | p.Asp122Gly | p.D122G | Q9UKR3 | protein_coding | tolerated(0.13) | probably_damaging(0.974) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |